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with maternal hypertension. Early diagnosis and treatment through regular ante-
natal check-up is a key factor to prevent PIH and its complications. Interventions to 
improve maternal health through information, education and counselling of women 
of child bearing age should be implemented.
CardiovasCular disorders – Cost studies
PCv45
estimating the Budget imPaCt of ClevidiPine for the management of 
PerioPerative Blood Pressure in CardiaC surgery: a us PersPeCtive
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Objectives: Increased perioperative blood pressure (BP) variability in cardiac sur-
gery is associated with negative clinical outcomes and increased health resource 
utilization (HRU). Clevidipine, an ultrashort-acting, arterial selective calcium chan-
nel blocker reduces BP variability and may reduce HRU in this setting. The current 
model evaluates the one year budget impact of adding clevidipine to an intrave-
nous antihypertensive (IVAH) treatment mix in a sample US hospital. MethOds: 
A spreadsheet model was developed using treatment specific HRU data from a 
clevidipine clinical trial (ECLIPSE) in cardiac surgery. Treatment distribution for 
IVAH agents (clevidipine, nicardipine, nitroglycerin, and nitroprusside), case vol-
umes and comparable IVAH dosages were obtained from the Premier Hospital 
database. Unit costs for IVAH are US Wholesale Acquisition Costs (WAC). Thirty-
day event costs were from the published literature. The model inputs may be 
customized to more accurately represent a given healthcare system. Results: 
The base case assumed a sample hospital with 468 coronary artery bypass graft 
(CABG) cases and 322 heart valve (HV) cases annually. Clevidipine usage in the 
base case was minimal (0% in CABG; 1% in HV). The base case predicts a one year 
total cost of $19,045,453 with the largest proportion of costs from general ward, 
ICU and operative suite time (approx. 30%, 21%, and 20% respectively). One year 
IVAH costs totaled $93,958 or 0.5% of total costs. Increasing the proportion of cases 
receiving clevidipine to 5% for both procedures increased drug acquisition costs 
by $13,005 and decreased HRU-related costs by $48,439 for a net decrease in costs 
of $35,434 for one year. cOnclusiOns: This analysis predicts a net savings with 
an increase in clevidipine use. In this example case, a minimal increase in IVAH 
costs was offset by savings in HRU-related costs resulting from improved outcomes 
associated with reduced perioperative BP variability.
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Objectives: To construct a budget impact model (BIM) to evaluate the economic 
impact of a combination of 5% albumin and crystalloids compared to crystalloids 
alone as fluid therapy administered to patients within one day of undergoing on-
pump coronary artery bypass graft (CABG) and/or valve procedures. MethOds: 
Model parameters were obtained from clinical outcomes determined from a pro-
pensity-matched retrospective US electronic health record (EHR) database (Health 
Facts, Cerner) analysis performed to assess the differences in patient outcomes 
for those who received albumin and crystalloid solutions versus crystalloids alone 
for fluid therapy post cardiac surgery. The BIM was developed to evaluate the eco-
nomic impact of increased usage of 5% albumin for volume therapy within one 
day of undergoing on-pump cardiac surgery. The model utilizes economic costs for 
treating complications obtained from published literature and reports as well as 
data from the EHR database analysis. The BIM covers a 2-year period and presents 
annual and cumulative costs from both a total hospital and total pharmacy perspec-
tive. Results: A base case analysis for a hospital performing 100 cardiac surgeries 
per month results in a 2-yr cumulative savings of $1.32MM, assuming that 70% 
of patients require fluid resuscitation. The increased fluids cost associated with 
increased 5% albumin utilization is offset by reduced costs in hospital readmissions 
and treating fewer complications of pneumonia, acute kidney injury (AKIN stage 
III) and electrolyte abnormalities. In-hospital mortality was significantly lower in 
patients receiving 5% albumin (2.4% vs. 4.1% for crystalloids alone, p= 0.02) which is 
reported strictly as a clinical outcome within the model. cOnclusiOns: There are 
both clinical and economic advantages associated with increased utilization of 5% 
albumin for fluid therapy in patients following on-pump cardiac surgery. Hospital 
analysis of cardiac procedure outcomes and economics is particularly relevant given 
recent CMS value-based purchasing initiatives.
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Objectives: To estimate the expected cost of the pharmacological treatment 
on prevalence of arterial hypertension (AH), diabetes mellitus (DM) and dyslipi-
demia in the Chilean population, following the recent approval of Drug National 
Funds. MethOds: The drugs considered in this study and the information about it, 
were obtained through a review of clinical guideline or technical norms published by 
the health ministery of Chile. The cost was estimated using the drug consumption 
patterns from the national health survey 2009-2010 and from a vector of prices for 
every drug and their combination of uses, for both public and private health sys-
tems through the public market platform and IMS health Chile. 10.000 Montecarlo 
could be a potential link between lipid metabolism and liver diseases, which neces-
sitate further investigation.
PCv42
statin use and risk of develoPing diaBetes: a netWork meta-
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Objectives: Studies have shown that statins may induce diabetes in non-diabetic 
cardiovascular disease patients, as class effect. It is uncertain if any particular statin 
is more likely to have greater risk of developing diabetes; only direct and indirect 
comparison of treatment effects may clarify this uncertainty. We had previously con-
ducted a systematic literature review to estimate the relative likelihood of statin vs. 
placebo or other agents. This network meta-analysis (NMA) was conducted to rank 
the treatments according to their risk of developing diabetes. MethOds: We searched 
databases like Embase, PubMed, and Cochrane. Randomized controlled trials that 
studied one of the statins and reported incidence of diabetes as an outcome were 
considered for inclusion. Data synthesis was performed by pairwise meta-analysis 
and NMA using STATA® with routines available from www.mtm.uoi.gr. Results: 
Twelve trials were included in this review, in which 78,677 participants had been 
randomized. The follow-up ranged from two to nine years among the studies. As 
previously reported the pair-wise meta-analysis showed that statins significantly 
increased the odds of developing diabetes compared to placebo without considerable 
heterogeneity [OR 1.15; 95% CI 1.06, 1.25; p= 0.0006; I250%]. From the present NMA, the 
drug with highest odds for developing diabetes was simvastatin 80mg [OR 5.24; 95% 
credible intervals (CrI) 1.28, 21.46], followed by simvastatin 20mg [OR 4.89; 95% CrI 
1.20, 19.91], atorvastatin 80mg [OR 1.29; 95% CrI 1.00, 1.67], rosuvastatin [OR: 1.22, 95% 
CrI 1.05, 1.43] compared to placebo. Atorvastatin 10mg and pravastatin did not signifi-
cantly increase the risk of diabetes in the network meta-analysis. cOnclusiOns: 
To the best of our knowledge, this is the first study exploring this correlation. The 
NMA shows the risk of developing diabetes to be higher with simvastatin. However, 
this should be confirmed from observational studies using a large safety database.
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Objectives: To assess in a community setting the clinical characteristics, the out-
comes and the related costs of patients admitted for an acute coronary syndrome 
(ACS) or a stroke/TIA (CVD) or a peripheral artery disease (PAD). MethOds: From the 
ARNO Observatory, we carried out a record linkage analysis of discharge records for 
ACS and prescription databases, which included 2,989,512 subjects of 7 Local Health 
Authorities from Northern to Southern Italy. The accrual period lasted from January 
1 to December 31, 2011. Results: Of the 2,989,512 subjects, 6,226 (2.1‰) were hos-
pitalized for ACS, 9,939 (3.3‰) for a CVD and 1,048 (0.4‰) for PAD. Patients admitted 
for CVD were significantly older and of female gender than patients with ACS or PAD 
(age 75 ± 13 vs 71 ± 13 vs 73 ± 11, p< 0.001) (gender 50.6% vs 35.5% vs 31.9%, p < 0.001). 
In-hospital mortality rate was 6.9%, 4.6% and 1.0% (p< 0.001) respectively for CVD, 
ACS and PAD. Over the 1-year follow-up, 63.3% of the patients with ACS needed to be 
readmitted again vs 49.1 of those with CVD and 57.6% of PAD. The average yearly cost 
per patient for the ACS population was 16,897€ /year (drugs, 1,692€ ; hospitalizations, 
14,198€ ; diagnostic and outpatient visits, 1,007€ ), for the CVD 10,440€ /year (drugs, 
1,135€ ; hospitalizations, 8,745€ ; diagnostic and outpatient visits, 560€ ) and for PAD 
14,872€ /year (drugs, 1,649€ ; hospitalizations, 11,781€ ; diagnostic and outpatient vis-
its, 1,442€ ). cOnclusiOns: In a large and representative community setting, CVD 
patients have a worse in-hospital outcome than patients with ACS or PAD. However, 
the costs for the NHS were higher for patients with ACS or PAD being the main cost 
driver the need for further readmissions during the follow-up period.
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Objectives: The objective of this thesis is to study and evaluate the Dug utiliza-
tion pattern and clinical outcome in pregnancy induced hypertension in tertiary 
care hospitals. MethOds: This Retrospective observational study was carried 
out in department of obstetrics and gynecology, CKM and Vishwas hospital, S.V.R. 
Hospital, warangal. Data were collected as per inclusion and exclusion criteria 
and analyzed for drug utilization pattern of antihypertensive drugs with their 
teratogenic risk category as well as for WHO drug use indicators at initiation and 
during entire study period. Neonatal morbidity and mortality outcome was also 
assessed. Results: Out of the 165 total prescriptions studied majority were in age 
group 21-25years,illiterates and low income group. The most commonly prescribed 
antihypertensive Monotherapy was Methyldopa (35.1%) followed by Nifedipine 
(18.78%). Labetolol and Nifedipine combination was most commonly used multi 
drug regimen(9.69%). Majority drugs prescribed were from category B and C. Average 
number of drugs per prescription are five. Single drug therapy was prescribed in 
72.21 % patients.50% of the drugs are from WHO essential drug list of 18th edition. 
The most common neonatal outcome was low birth weight (84.88%), followed by 
fetal distress (9.30%), neonatal deaths(3.48%) and IUGR(2.32%).A significant correla-
tion was found between Diastolic blood pressure of mother and neonatal morbidity 
and mortality rate. cOnclusiOns: Methyldopa was the commonly prescribed anti-
hypertensive in monotherapy as well as combination for PIH. This necessitates the 
development, implementation, and evaluation of policies on the use of antihyper-
tensive drugs. The incidence of high neonatal morbidity and mortality is associated 
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Objectives: To assess the economic burden and health care resource utili-
zation among patients in long-term care facilities who were diagnosed with 
stroke. MethOds: Patients diagnosed with stroke (International Classification of 
Diseases, 9th Revision, Clinical Modification diagnosis codes 433, 434 and 436) were 
identified using the Long Term Care Minimum Data Set (MDS) linked to 5% Medicare 
data from 01JAN2009 through 31DEC2010. The initial diagnosis date was designated 
as the index date. Patients without a stroke diagnosis (control cohort) were matched 
to stroke patients, and 1:1 propensity score matching (PSM) was used to control for 
age, region, gender and baseline Charlson Comorbidity Index score. The index date 
for the control cohort was randomly chosen to reduce selection bias. Patients in 
both cohorts were required to be age ≥ 65 years, have at least two consecutive quar-
terly assessments documented in MDS data 6 months prior to the index date and 
have continuous medical and pharmacy benefits 1 year before and after the index 
date. Results: Once PSM was applied, 1,014 patients were included in each cohort, 
and baseline characteristics were balanced. A higher percentage of stroke patients 
had inpatient admissions (40.34% vs. 23.37%, p< 0.0001), outpatient visits (92.31% 
vs. 89.45%, p= 0.0253), skilled nursing facility (SNF; 37.67% vs. 28.21%, p< 0.0001) and 
durable medical equipment (DME) claims (30.47% vs. 22.09%, p< 0.0001) than those 
in the control cohort. Stroke patients also incurred considerably higher inpatient 
($7,068 vs. $3,418, p< 0.0001), outpatient ($3,545 vs. $2,539, p< 0.0001), SNF ($8,036 vs. 
$3,695, p< 0.0001), DME ($394 vs. $235, p= 0.0023) and carrier claim costs ($3,606 vs. 
$2,489, p< 0.0001) than those without a stroke diagnosis. cOnclusiOns: Patients 
diagnosed with stroke had considerably higher health care resource utilization and 
costs than those in the control cohort.
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AND DIABETES IN NIGER DELTA: TERTIARY HOSPITAL BASED STUDY IN BAYELSA 
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Objectives: To assess the economic burden of the management of hypertension 
and diabetes in two tertiary health facilities in Bayelsa State, Niger Delta, South-
south Nigeria. MethOds: It is a retrospective review of randomly selected case 
notes of 531 hypertensive and diabetic patients. The demographics and cost of 
medicines prescribed were reviewed based on the hospital prices. These patients 
were randomly selected from those who attended the endocrinology and cardiol-
ogy clinics of the health facilities in 2011 and 2012. Results: Mean patients’ age 
was 55.70±12.23 years. Most (42.2%) of them were civil servants while the rest were 
petty business owners (26.6%), retired workers (14.9%), farmers (10.3%), or unem-
ployed (6%). The monthly average costs of all prescribed medications per patient 
for initiation and maintenance of therapy were ₦3333.43±2317.40 (US$18.17±12.60) 
and ₦4458.09±3064.8 (US$24.30±16.70) respectively (p < 0.05). Diuretics and sulpho-
nylureas were the most economical of all the drugs prescribed monthly per patient 
accounting for ₦531.70 [US$2.90] and ₦559.10 [US$3.10] respectively for initiation 
of therapy, and ₦768.1 [US$4.20] and ₦631.1 [US$3.40] for maintenance of therapy. 
However, the most expensive of all the medicines were angiotensin receptor blockers 
which accounted for ₦4,368.8 [US$23.8] for initiation and ₦4,810.50 [US$26.20] for 
maintenance of therapy as well as insulins (at ₦2,448.20 [US$13.30] for initiation 
and ₦2,457.10 [US$13.40] for maintenance of therapy). cOnclusiOns: Considering 
the poverty level in the Niger Delta region of Nigeria, the medication cost burden 
of managing hypertension and diabetes is high and unaffordable by most of the 
patients.
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Objectives: Giant cell arteritis (GCA), a chronic vasculitis commonly presenting 
with headache, affects approximately 230,000 individuals in the US. However, lim-
ited data exist on the health care resource utilization and costs that are attributable 
to GCA. The objective of this study was to estimate the cost of illness in patients with 
GCA in the US. MethOds: A retrospective cohort of patients with a new diagnosis 
of GCA and five matched controls was identified from a large US claims database 
between January 1st 2008 and December 31st2011. Newly diagnosed GCA patients 
were defined by a diagnosis of GCA (ICD-9 446.5) during the study period and no GCA 
diagnosis in the 12 months prior. Controls were defined by absence of a GCA diag-
nosis. GCA patients and controls were matched on age, gender, region, index year of 
diagnosis, and index month of diagnosis. One-year healthcare costs were compared 
among cases and controls, adjusting for age, gender, Charlson Comorbidity Index 
(CCI), chronic disease count, U.S. region, health plan type (HMO vs. other), and year 
using generalized linear models. Results: A cohort of 11,245 GCA patients and 
56,230 controls was identified. The mean age of the cohort was 70 years and 71% 
were females. Mean CCI was 1.6 for GCA patients and 0.8 for controls. Mean one-
year cost for GCA patients was $26,400 (SD: $48,500) and mean one-year cost for 
controls was $11,500 (SD: $29,200). After multivariate adjustment, the difference 
in one-year cost between GCA patients and controls was $4,800 (95% CI: $4,080—
$5,520). cOnclusiOns: Patients with GCA experience increased healthcare costs 
compared to patients without GCA after adjusting for covariates related to health 
care resource utilization and costs. Our results are the first to inform researchers, 
clinicians, and policymakers on the cost burden of GCA, estimated to be approxi-
mately $1 billion annually in the US.
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simulations were performed to propagate the uncertainty of parameters. Results: 
The expected cost (and its credibility intervals of 95%) of the prevalent popula-
tion with AH, DM and dyslipidemia using prices from public health system 
was in Chilean pesos (CLP$) CLP$12,463MM (CLP$11,394MM – CLP$13,622MM), 
CLP$36,425MM (CLP$25,603MM – CLP$49,624MM) and CLP$20,658MM (CLP$11,090MM 
– CLP$33,284MM) respectively. While, the estimated cost based on private health 
system was CLP$700,613MM (CLP$561,764MM – CLP$865,354MM), CLP$333,921MM 
(CLP$253,963MM – CLP$436,879MM) and CLP$680,919MM (CLP$327,916MM – 
CLP$1,645,906MM) respectively. cOnclusiOns: The expected cost needed for the 
treatment of the three conditions studied represent 1.3% and 2.9% in the worst case 
scenario (33% considering private system prices) of the 2014 health budget, and the 
effort to improve the subdiagnostic of these conditions would determine a budget 
impact of at least 0.86%, only with pharmacological treatment.
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Objectives: Systemic arterial hypertension (SAH) is a chronic condition, and 
despite the large number of available antihypertensive drugs, patients with SAH 
who are drug-treated frequently do not obtain goal Blood Pressure (BP) levels. A 
combination of drugs is recommended for those cases, however, compliance is 
improved when agents are prescribed as fixed dose combinations rather than sepa-
rate pills. A combination of bisoprolol and amlodipine once a day showed a rapid 
reduction of BP after 4 weeks. The aim of this paper is to perform cost-effectiveness 
(CE) and budget impact (BI) analyses of Concor® AM compared to amlodipine + 
bisoprolol as separate tablets. MethOds: A daily-cycle markov model was built 
considering the outcomes: days on treatment; number of events (stroke, myocardial 
infarction, heart failure and angina); number of full-lifetime-patients with transitory 
drug interruption (non-compliance); number of full-lifetime-patients with normal 
blood pressure and days of life. Efficacy data were obtained from literature review 
and unit costs were obtained from official price lists. The time horizon of the CE 
and BI model was 30 and 10 years, respectively. A 5% annual discount rate was 
applied in costs and benefits in the CE model. Results: Concor® AM increased 
overall survival in 43 days and assured more 2,090 days on treatment, per patient, 
during lifetime period. Also, reduced 183 events, and allowed more 187 patients 
with controlled blog pressure, per 1,000 patients. Concor® AM was dominant vs. 
Concor + Amlodipine, resulting in financial resource saving of approximately 8.1% 
(BRL 5,720.72 per patient). Additionally, the use of Concor® AM in patients with 
SAH resulted in financial resource saving of approximately BRL 300,321,412.45, in 
the period from 2014 to 2025. cOnclusiOns: Fixed-dose combinations such as 
Concor-AM do represent an opportunity to increase compliance and consequently 
health outcomes and its costs.
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Objectives: The objective of this study was to estimate the overall differences 
in medical costs when nonvalvular atrial fibrillation and venous thromboembo-
lism (VTE) patients are treated with each of the new oral anticoagulants (NOACs), 
dabigatran, rivaroxaban, apixaban, and edoxaban vs. warfarin. MethOds: Medical 
cost differences associated with NOAC use for patients treated for NVAF and acute 
VTE were obtained from previous publications and were based on clinical event 
rates from clinical trials. The medical cost differences associated with edoxaban 
vs. warfarin among NVAF patients were estimated as done previously for other 
NOACs. A hypothetical health plan population with 1 million members was used to 
estimate and compare the medical cost differences associated with use of each of 
the NOACs vs. warfarin among the combined NVAF and VTE populations. Prevalence 
rates of NVAF and VTE were derived from published literature. The same hypotheti-
cal usage rate (i.e. 10%) for each NOAC was assumed to facilitate the comparison of 
the medical cost differences. The medical cost differences of NOACs vs. warfarin 
were projected in the years 2015-2018. Results: In 2014, in a hypothetical popula-
tion of 1 million health plan members, medical costs were estimated to be reduced 
by the greatest amount for NVAF and VTE patients treated with apixaban ($11.5 
million), followed by those treated with edoxaban ($6.6 million), rivaroxaban ($4.2 
million), and dabigatran ($3.7 million). Medical cost savings associated with use of 
any of the NOACs were projected to increase from 2014 to 2018. cOnclusiOns: 
Based on our economic analysis using clinical trial data, treatment of patients with 
NVAF and VTE with any of the NOACs instead of warfarin is associated with sav-
ings in medical costs, with apixaban being associated with the greatest savings in 
medical costs. The direct application of the results to the real-world setting will 
require further assessment.
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